Medtronic on September 1, 2026 committed approximately $700 million to Hong Kong-based Cornerstone Robotics, gaining exclusive distribution rights for the Sentire surgical system in select markets outside the United States where the platform holds regulatory approval1,2,4. The deal creates a dual-platform robotic surgery portfolio pairing Medtronic's Hugo RAS system with Cornerstone's Sentire, which integrates AI-driven autonomous capabilities tested in peer-reviewed research12.
The AI dimension of the deal centers on Sentire's technical architecture. Cornerstone has built what it describes as a fully vision-based embodied AI framework, tested in Science Robotics, for autonomous grasping, retraction, and vessel clipping. Medtronic said it plans to continue developing Hugo with real-time artificial intelligence across its digital ecosystem, alongside software upgrades, integrated stapling, and expanded instrumentation14. Matt Anderson, senior vice president and president of surgical at Medtronic, said the company is "investing across robotic platforms, digital tools and platform-enhancing technologies".
Sentire received approval from China's National Medical Products Administration in 2024, followed by CE Mark certification in the European Union and approval from Singapore's Health Sciences Authority in May 2026 for minimally invasive general, gynecologic, thoracic, and urologic procedures5,6,10. Hugo received FDA clearance for urologic procedures in December 2025 and is now deployed in more than 35 countries across six continents.
Cornerstone follows a vertically integrated, full-stack development model with in-house capabilities spanning hardware, control software, advanced algorithms, imaging, and energy platforms. The company operates three global R&D hubs, six business centers, and a 30,000-square-meter manufacturing facility in Shenzhen, China. Cornerstone completed an oversubscribed $200 million financing round in November 2025.
Sentire's technical specifications include a single integrated central column supporting four articulated manipulator arms with 540-degree spatial rotation, Master Grip 2.0 direct-drive magnetic gimbal controllers with seven degrees of freedom, interchangeable 8mm tools and 5mm micro-wristed instruments with eight degrees of freedom, and an 8mm 4K 3D stereoscopic vision engine with real-time indocyanine green fluorescence imaging. The system comprises 13,000 components, and Cornerstone claims a 99% self-development and self-manufacturing ratio for core components.
Medtronic secured a board seat at Cornerstone Robotics as part of the arrangement. Morgan Stanley & Co. LLC served as exclusive financial advisor to Medtronic, with Cleary Gottlieb Steen and Hamilton as lead legal counsel; Kirkland & Ellis and Global Law Office advised Cornerstone.
The investment landed alongside strong quarterly results. Medtronic reported fiscal 2027 first-quarter revenue of $9.76 billion, up 14% year-over-year, with adjusted earnings per share of $1.4515. The company raised its full-year organic revenue growth outlook to 7.25%–7.75% and narrowed adjusted EPS guidance to $5.94–$6.00. Hugo procedure growth is running at more than twice the rate of the broader robotic surgery market, with total Hugo procedures expected to surpass 50,000 globally by the end of Medtronic's fiscal year.
BioWorld reported that Medtronic committed a total of $780 million in new deals spanning surgical robotics and structural heart disease, including an $80 million investment in Pi-Cardia with an option to acquire the company for $210 million3.
ANALYSIS The Sentire deal gives Medtronic a second robotic platform with broader international clearances than Hugo currently holds, filling a multispecialty gap outside the United States while Cornerstone's embedded AI framework adds autonomous surgical capabilities that Medtronic's own Hugo roadmap is still developing. The board seat and exclusive distribution rights tie the two companies tightly enough that the arrangement functions as a de facto acquisition of Cornerstone's international commercial channel.